Amanda Kogelman is a pharmacist who is specialized in Oncology in Traverse City, Michigan. Patients can reach her at 217 S Madison St, Traverse City or contact her on 231-935-6734. Active license number of Amanda Kogelman is 5302038862 for Oncology in Michigan. Amanda Kogelman is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Amanda Kogelman speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Amanda Kogelman
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
217 S Madison St, Traverse City, Michigan, 49684-2321
Phone:
231-935-6734
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Amanda Kogelman are as mentioned below.
NPI Number:
1730424979
NPI Enumeration Date:
28 Nov, 2012
NPI Last Update On:
10 Jun, 2025
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Amanda Kogelman are as mentioned below.
Specialization
License Number
State
Status
Oncology
5302038862
Michigan
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
323 S Garfield Ave, Unit A Traverse City, Michigan
Zip:
49686-2932
Phone Number:
231-349-7949
Fax Number:
--
Patients can reach Amanda Kogelman at 217 S Madison St, Traverse City, Michigan or can call on phone at 231-935-6734.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.